WOCKHARDT LTD. - 532300 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Humuza Consultants & Habil Khorakiwala Trust (shares held through Themisto Trustee Co. Pvt Ltd and PACs 
Glenmark acquires Wockhardt's key OTC brands in US for undisclosed sum
Deal includes approved ANDAs for famotidine tablets, used in treatment and prevention of ulcers stomach and intestinal ulcers WOCKHARDT LTD. - 532300 - Pursuant To Regulation 23(9) Of Listing Regulations, Please Find Attached The Statement Regarding Disclosure Of Related Party Transactions In The Specified Format For The Half Year Ended 31St March, 2022 Of The Company
Pursuant to Regulation 23(9) of Listing Regulations, please find attached the Statement regarding disclosure of Related Party Transactions in the specified format for the half year ended 31st March, 2022 of the Company WOCKHARDT LTD. - 532300 - Outcome Of Board Meeting Held On 7Th June, 2022 - Change In CFO
Pursuant to Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''Listing Regulations') we wish to inform you that Mr. Pramod Gupta has conveyed that on account of his health reasons he will not be able to continue in his role as the Chief Financial Officer of the Company and has been relieved from his responsibilities at the end of working hours on 6th June 2022. The Board of Directors of the Company at its meeting held today i.e. 7th June, 2022, took note of the same and approved the appointment of Mr. Deepak Madnani as the Chief Financial Officer of the Company with immediate effect. WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Extract of Newspaper Publication of Audited Consolidated Financial Results for the quarter and year ended 31st March, 2022. Q4FY22 Quarterly Result Announced for Wockhardt Ltd.
Pharmaceuticals firm Wockhardt declares Q4FY22 result: Wockhardt’s FY22 Revenue grew by 17% over FY21. Long Term Debt reduced by Rs 450 Cr. Successful Rights Issue of Rs.748 Cr. The Company recorded a Revenue of Rs.655 Cr registering a growth of 4% compared to previous corresponding quarter and an EBITDA of Rs. (33) Cr compared to Rs. (80) Cr in the corresponding quarter of the previous year. There is Revenue growth of 17% in FY22 over the previous year and substantial improvement in EBITDA at Rs.298 Cr. During the quarter, the company also successfully completed its Rights Issue of Rs. 748 Cr which was fully subscribed. Company used these proceeds to significantly reduce debt and strengthen the balance sheet. Result PDF 
Wockhardt Q4 loss widens to Rs 311 crore even as income rises marginally
Pharmaceuticals firm Wockhardt Ltd on Monday reported widening of consolidated net loss to Rs 311 crore in the fourth quarter ended March 31, 2022. WOCKHARDT LTD. - 532300 - Audited Financial Results For The Quarter And Year Ended 31.03.2022.
Audited Financial Results For The Quarter And Year Ended 31.03.2022.